Trial · NCT05014672
Adverse events96
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 96
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasopharyngitis | Infections and infestations | Setanaxib 1200 mg/Day | 3 | 25 | |
| other | Nasopharyngitis | Infections and infestations | Setanaxib 1600 mg/Day | 4 | 25 | |
| other | Nasopharyngitis | Infections and infestations | Placebo | 0 | 26 | |
| other | COVID-19 | Infections and infestations | Setanaxib 1200 mg/Day | 3 | 25 | |
| other | COVID-19 | Infections and infestations | Setanaxib 1600 mg/Day | 3 | 25 | |
| other | COVID-19 | Infections and infestations | Placebo | 0 | 26 | |
| other | Influenza | Infections and infestations | Setanaxib 1200 mg/Day | 0 | 25 | |
| other | Influenza | Infections and infestations | Setanaxib 1600 mg/Day | 2 | 25 | |
| other | Influenza | Infections and infestations | Placebo | 0 | 26 | |
| other | Upper respiratory tract infection | Infections and infestations | Setanaxib 1200 mg/Day | 0 | 25 | |
| other | Upper respiratory tract infection | Infections and infestations | Setanaxib 1600 mg/Day | 2 | 25 | |
| other | Upper respiratory tract infection | Infections and infestations | Placebo | 0 | 26 | |
| other | Urinary tract infection | Infections and infestations | Setanaxib 1200 mg/Day | 0 | 25 | |
| other | Urinary tract infection | Infections and infestations | Setanaxib 1600 mg/Day | 0 | 25 | |
| other | Urinary tract infection | Infections and infestations | Placebo | 2 | 26 | |
| other | Gastroenteritis viral | Infections and infestations | Setanaxib 1200 mg/Day | 0 | 25 | |
| other | Gastroenteritis viral | Infections and infestations | Setanaxib 1600 mg/Day | 2 | 25 | |
| other | Gastroenteritis viral | Infections and infestations | Placebo | 0 | 26 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Setanaxib 1200 mg/Day | 2 | 25 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Setanaxib 1600 mg/Day | 4 | 25 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05014672/events